Moderna-Merck Melanoma Vaccine Shows Lower Relapse Risk in Late-Stage Trial
Moderna and Merck's personalized mRNA melanoma vaccine demonstrated a reduction in relapse risk during a late-stage trial, according to a report from KRCR covering Eureka.
Eureka, CA, October 23, 2026 —
A personalized mRNA melanoma vaccine developed by Moderna and Merck demonstrated a reduction in relapse risk during a late-stage trial, according to a report from KRCR covering Eureka.
The report, as summarized, does not provide the size of the reduction or other trial results. It also does not specify how many people took part, how long they were followed, or how the vaccine was compared with other treatment. The trial’s name and the date of the report were not provided.
The summary describes the finding as a reduction in relapse risk but does not clarify the measure used or whether the result was statistically significant. It does not state whether the trial met its primary endpoint, or provide details about safety findings, the treatment protocol, or plans for further study.
The vaccine is described as personalized and based on mRNA technology. No further information was provided about how it is made, which patients were included, or when it might be available. The summary also does not provide statements from Moderna, Merck, researchers, regulators, or patients.
As a result, the available information establishes the reported direction of the trial finding but does not provide enough detail to assess its scale or implications. Additional trial results and company or regulatory information were not included in the report summary.
Story summarized from the original created by Google News on news.google.com, see more information here.
